DRUG-RELATED LUPUS - INCIDENCE, MECHANISMS AND CLINICAL IMPLICATIONS

被引：36

作者：

ADAMS, LE ^{[1
]}

HESS, EV ^{[1
]}

机构：

[1] UNIV CINCINNATI,MED CTR,DEPT INTERNAL MED,DIV IMMUNOL,231 BETHESDA AVE,ML 564,CINCINNATI,OH 45267

来源：

DRUG SAFETY | 1991年 / 6卷 / 06期

关键词：

D O I：

10.2165/00002018-199106060-00004

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Adverse side effects to drugs and chemicals in which immune mechanisms may be responsible have been described in drug-related lupus (DRL). The spectrum of drugs that may elicit DRL includes such classes as the hydrazines, arylamines, and chemicals that can be metabolised to amines. The 2 major pathways of metabolism - acetylation and N-hydroxylation - are described in detail. The events leading to autoantibody production are not well understood; however, specific consideration of the genetic makeup of patients who are candidates for treatment with these drugs may help identify those at risk of developing DRL.

引用

页码：431 / 449

页数：19

共 163 条

[1]

Ada L.E., Roberts S.M., Carter J.M., Wheeler J.F., Et al., Effects of procainamide hydroxylamine on generation of reactive oxygen species by macrophages and production of cytokines, International Journal of Immunopharmacology, 12, pp. 809-819, (1990)

[2]

Ada L.E., Sanders C.E., Budinsky R.A., Donovan-Brand R.J., Hess E.V., Immunomodulatory effects of procainamide metabolites: their implications in drug-related lupus, Journal of Laboratory and Clinical Medicine, 113, pp. 482-492, (1989)

[3]

Alarcon-Segovia D., Drug-induced antinuclear antibodies and lupus syndrome, Drugs, 12, pp. 69-77, (1976)

[4]

Alarcon-Segovia D., Drug-induced lupus syndrome, Mayo Clinic Proceedings, 44, pp. 664-681, (1969)

[5]

Alarcon-Segovia D., Wakim K.G., Worthington J.W., Ward L.E., Clinical and experimental studies on the hydralazine syndrome and its relationship to systemic lupus erythematosus, Medicine, 46, pp. 1-33, (1967)

[6]

Allan I.M., Lunec J., Salmon M., Bacon P.A., Selective lymphocyte killing by lack of reactive oxygen species (ROS), Agents and Actions, 19, pp. 351-352, (1986)

[7]

Allison A.C., Unresponsiveness to self-antigen, Lancet, 2, pp. 1401-1403, (1971)

[8]

Alvan G., Individual differences in the disposition of drugs metabolised in the body, Clinical Pharmacokinetics, 3, pp. 155-175, (1978)

[9]

Alvan G., von Bahr C., Seidman P., Et al., High plasma concentrations of β-receptor blocking drugs and deficient debrisoquine hydroxylation, Lancet, 1, (1982)

[10]

Andersson M., Hanson A., England G., Et al., Inhibition of complement components C3 and C4 by cadralazine and its active metabolites, European Journal of Clinical Pharmacology, 40, pp. 261-265, (1991)

← 1 2 3 4 5 6 7 8 9 10 →